Is BeyondSpring, Inc. overvalued or undervalued?

As of 13 August 2025, BeyondSpring, Inc. has moved from a risky valuation grade to one that does not qualify. The company is considered overvalued given its negative valuation ratios, including a Price to Book Value of -2.42, an EV to EBIT of -6.89, and an EV to EBITDA of -7.12. In comparison, peers such as Checkpoint Therapeutics, Inc. have an EV to EBITDA of -5.9896, while Journey Medical Corp. shows a more extreme EV to EBITDA of -25.5082, indicating that BeyondSpring is not only underperforming but also not justifiably valued in its sector.
Recent stock performance further underscores this valuation concern, as BeyondSpring has experienced a 1-year return of -19.44%, compared to the S&P 500's gain of 17.14%. This stark contrast in returns highlights the challenges the company faces in the current market environment.